|Bid||73.10 x 500|
|Ask||74.88 x 100|
|Day's Range||73.19 - 74.42|
|52 Week Range||63.76 - 88.85|
|PE Ratio (TTM)||7.86|
|Dividend & Yield||2.08 (2.82%)|
|1y Target Est||N/A|
Glaxo shares dipped near a two-week low after Gilead's HIV drug combination proved to be non-inferior in a late-stage trial.
Hint: The list doesn't include higher sales for its hepatitis C franchise.
Gielad Sciences (GILD) reported trial data for an HIV treatment this morning, and it wasn't the blockbuster many might have hoped it would be. That doesn't mean it's a total loss, either. BMO analysts ...